Table 1. Patient baseline... | American Society of Hematology

Table 1.

Patient baseline characteristics, treatments, and outcomes

Characteristic	All patients (N = 400)		European LeukemiaNet risk groups
	All patients (N = 400)		Favorable (n = 29)		Intermediate (n = 230)		Adverse (n = 141)
	No.	%	No.	%	No.	%	No.	%
Age, y
Median (IQR)	65 (55-72)		53 (48-67)		55 (55-74)		65 (56-72)
>75	74	19	2	7	50	22	22	16
Sex
Male	225		15		129		81
Female	175		14		101		60
ECOG performance status
0-1	334	84	27	93	192	83	115	82
≥2	41	10	2	7	24	10	15	11
Unknown	25	6	0	0	14	6	11	8
Median peripheral blasts (IQR), %	6 (0-28)		22 (6-53)		30 (0-24)		6 (1-24)
Median bone marrow blasts (IQR), %	38 (25-64)		66 (39-74)		29 (25-61)		35 (22-64)
Mutations
FLT3-ITD/TKD	75	35821	16	2857	44	20821	15	12213
IDH1/2	42	16625	4	1527	27	8532	11	6617
First-line regimens
Intensive chemotherapy only	114	29	12	41	67	29	35	25
With non-chemotherapy*	74	19	7	24	47	20	20	14
Hypomethylating agent only	58	15	2	7	29	13	27	19
With chemotherapy	6	2	0	0	5	2	1	1
With non-chemotherapy	45	11	2	7	24	10	19	13
Nonintensive chemotherapy	82	21	5	17	46	20	31	22
And/or non-chemotherapy	21	5	1	3	12	5	8	6
Targeted therapies
FLT3 inhibitor	19	7520	4	1625	10	4416	5	1527
IDH1/2 inhibitor	0	420	0	40	0	270	0	110
Allogeneic SCT	63	16	8	28	31	13	24	17
Outcomes
Overall response rate†	336	84	29	100	194	84	113	80
CR	286	72	26	90	164	71	96	68
CRi/MLFS	45	11	2	7	27	12	16	11
PR	5	1	1	3	3	1	1	1
Relapse	278	83	21	72	160	83	96	85
Median months of EFS censored at SCT	9.7		11.7		10.8		8.0
Median months of OS censored at SCT	17.6		18.8		19.2		14.5

Characteristic	All patients (N = 400)		European LeukemiaNet risk groups
	All patients (N = 400)		Favorable (n = 29)		Intermediate (n = 230)		Adverse (n = 141)
	No.	%	No.	%	No.	%	No.	%
Age, y
Median (IQR)	65 (55-72)		53 (48-67)		55 (55-74)		65 (56-72)
>75	74	19	2	7	50	22	22	16
Sex
Male	225		15		129		81
Female	175		14		101		60
ECOG performance status
0-1	334	84	27	93	192	83	115	82
≥2	41	10	2	7	24	10	15	11
Unknown	25	6	0	0	14	6	11	8
Median peripheral blasts (IQR), %	6 (0-28)		22 (6-53)		30 (0-24)		6 (1-24)
Median bone marrow blasts (IQR), %	38 (25-64)		66 (39-74)		29 (25-61)		35 (22-64)
Mutations
FLT3-ITD/TKD	75	35821	16	2857	44	20821	15	12213
IDH1/2	42	16625	4	1527	27	8532	11	6617
First-line regimens
Intensive chemotherapy only	114	29	12	41	67	29	35	25
With non-chemotherapy*	74	19	7	24	47	20	20	14
Hypomethylating agent only	58	15	2	7	29	13	27	19
With chemotherapy	6	2	0	0	5	2	1	1
With non-chemotherapy	45	11	2	7	24	10	19	13
Nonintensive chemotherapy	82	21	5	17	46	20	31	22
And/or non-chemotherapy	21	5	1	3	12	5	8	6
Targeted therapies
FLT3 inhibitor	19	7520	4	1625	10	4416	5	1527
IDH1/2 inhibitor	0	420	0	40	0	270	0	110
Allogeneic SCT	63	16	8	28	31	13	24	17
Outcomes
Overall response rate†	336	84	29	100	194	84	113	80
CR	286	72	26	90	164	71	96	68
CRi/MLFS	45	11	2	7	27	12	16	11
PR	5	1	1	3	3	1	1	1
Relapse	278	83	21	72	160	83	96	85
Median months of EFS censored at SCT	9.7		11.7		10.8		8.0
Median months of OS censored at SCT	17.6		18.8		19.2		14.5

ECOG, Eastern Cooperative Oncology Group; ITD, internal tandem duplication; TKD, tyrosine kinase domain.

Non-chemotherapy agents included targeted therapies, tyrosine kinase inhibitors, immunotherapies, and other agents.

Overall response rate, CR + CRi + MLFS + PR.